Skin cancer drug gets NHS go-ahead
Linkedin

Skin cancer drug gets NHS go-ahead

Lugano : Switzerland | Nov 01, 2012 at 6:20 PM PDT
Source: Guardian Unlimited
XX XX
Views: Pending
 
The National Institute for Health and Clinical Excellence (Nice) turned down vemurafenib, sold by Roche under the brand name Zelboraf, in June because it offered only months of extra life for people with metastatic melanoma and cost £1,750 a week £91,000 a year. FULL ARTICLE AT Guardian Unlimited
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

News Stories

 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.